Oncology News | pharmaphorum

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

News

Mirati CEO David Meek steps down after Krazati setback

Mirati Therapeutics chief executive David Meek has agreed to step down by mutual agreement with the company's board, to be replaced on a temporary basis by founder and for

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

AI shows its value in mammography screening

A study has shown that artificial intelligence can be safely used to support mammography to spot breast cancers and may spot more tumours than the current standard approac

J&J bags first FDA approval for a GPRC5D drug

Mirati CEO David Meek steps down after Krazati setback

Arcus and Gilead drop A2R drug for prostate cancer

Astellas adds to cell therapy drive with Poseida deal

AZ and BMS resolve checkpoint inhibitor patent disputes

AI shows its value in mammography screening

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks